Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications

• Egile Nagusiak: Laura J. Waters (Egilea), John P. Hanrahan (Egilea), Joseph M. Tobin (Egilea), Catherine V. Finch (Egilea), Gareth M.B. Parkes (Egilea), Shamsuddeen A. Ahmad (Egilea), Faraj Mohammad (Egilea), Maria Saleem (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2018-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Three mesoporous silica excipients (Syloid® silicas AL-1 FP, XDP 3050 and XDP 3150) were formulated with a model drug known for its poor aqueous solubility, namely phenylbutazone, in an attempt to enhance the extent and rate of drug dissolution. Although other forms of mesoporous silica have been in...